CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 4 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 427 · Search date 2026-07-17 · Methodology v0.6

Oral glutathione,
does it really help with Liver detoxification, toxin elimination, and improvement in liver enzymes?

30-Second Summary
C
Evidence Grade C · 41 · Safety unknown
An uncontrolled ALT signal conflicts with null controlled trials, and higher body GSH does not prove actual liver detoxification
What the
research shows
Human literature is not entirely absent, but controlled trials do not support a liver-detoxification effect. In an open-label single-arm pilot that enrolled 34 patients with NAFLD and was completed by 29, ALT decreased after lifestyle intervention followed by glutathione 300 mg/day for four months; without a control group, lifestyle effects, changes over time, and regression to the mean cannot be separated. By contrast, an RCT in 40 healthy adults and an RCT in 61 patients with cirrhosis found no effects on glutathione or oxidative-stress measures. The conflict between a positive uncontrolled signal and null controlled trials places the evidence at the bottom of grade C.
What the
ads claim
Advertisements convert the biochemical role of glutathione or an increase in body stores into clinical promises of a 'liver cleanse,' 'toxin removal,' and improved liver enzymes. This liver-detoxification axis must be judged separately from other efficacy axes such as skin lightening.
*

Useful facts when choosing a product

  • Reduced, liposomal, and film products are sold in South Korea as conventional foods or imported supplements, commonly with labeled amounts ranging from 100 to 1,000 mg/day.
  • Human studies used 250-1,000 mg/day; the NAFLD pilot used 300 mg/day and the cirrhosis RCT used 500 mg/day.
  • Standard oral glutathione has low bioavailability, and absorption findings cannot be transferred across formulations.
  • Higher blood or cellular GSH does not establish actual liver detoxification or improved liver enzymes.
Gap Measurement · Verdict 427 · C 41
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 2011 Allen randomized double-blind placebo-controlled trial in 40 healthy adults found no significant effect on GSH status, F2-isoprostanes, or 8-OHdG after 500 mg twice daily for four weeks. The 2015 Richie RCT in 54 healthy adults reported increases in some body GSH stores with 250 or 1,000 mg/day for six months but did not measure clinical liver effects. The 2017 Honda NAFLD pilot was an open-label single-arm study that enrolled 34 participants and was completed by 29; it reported an ALT reduction after lifestyle intervention followed by 300 mg/day for four months, but it had no control group. The 2020 Lai RCT assigned 61 patients with cirrhosis to four groups, including 500 mg/day of glutathione, for 12 weeks and found no significant effect on oxidative-stress or antioxidant-capacity measures.

02

Why this is classified as C (41)

Human literature and an uncontrolled ALT signal in NAFLD rule out an ungraded verdict, but the single-arm study is heavily confounded by prior lifestyle intervention. Controlled RCTs in healthy adults and cirrhosis were null for GSH and oxidative-stress measures, and no actual clinical liver-detoxification outcome has been shown, resulting in the bottom of grade C with 41 points.

Counterpoint. The uncontrolled ALT signal and increase in body GSH stores justify a follow-up placebo-controlled liver-disease trial but do not establish a current clinical benefit.

Rejudgment record. Reassessment (cross-check reflected) — Human literature exists, but the positive NAFLD finding comes from an uncontrolled pilot after lifestyle intervention, while controlled RCTs in healthy adults and cirrhosis were null for GSH and oxidative-stress measures, placing limited and conflicting evidence at the bottom of grade C

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Raised body glutathione stores (surrogate)CControlled trials show raised body GSH, but this is a surrogate
Actual liver detox, liver-enzyme, or oxidative-stress improvementDControlled RCTs in healthy adults and cirrhosis were null; the only positive was an uncontrolled pilot

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Allen J, Bradley RD. 2011Randomized double-blind placebo-controlled trial39UnknownGSH status, F2-isoprostanes, and 8-OHdGNo significant between-group effect on GSH or either oxidative-stress marker after 500 mg twice daily for four weeks; liver detoxification was not measured.Key
Richie JP Jr et al. 2015Randomized double-blind placebo-controlled trial54Included industry supportGlutathione stores in blood and cellsSome body GSH stores increased with 250 or 1,000 mg/day; clinical liver effects were not measured.Supportive
Honda Y et al. 2017Multicenter open-label single-arm pilot29Included provision of the study ingredientALT, lipids, and surrogate liver-fat measuresALT decreased after lifestyle intervention followed by 300 mg/day for four months; the lack of a control group prevents exclusion of confounding.Key
Lai CY et al. 2020Double-blind randomized placebo-controlled four-group trial61Taiwanese public research grantsOxidative stress, antioxidant capacity, and Child-Turcotte-Pugh severityGSH 500 mg/day alone or in combination for 12 weeks had no significant effect on oxidative-stress or antioxidant-capacity measures.Key
§

Receipt — 4 References

All 4 cited sources were verified for existence at the original page (as of 2026-07-17).

Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011;17(9):827-833. PMID: 21875351. DOI: 10.1089/acm.2010.0716.
checked
Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-263. PMID: 24791752. DOI: 10.1007/s00394-014-0706-z.
checked
Honda Y, Kessoku T, Sumida Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017;17:96. PMID: 28789631. DOI: 10.1186/s12876-017-0652-3.
checked
Lai CY, Cheng SB, Lee TY, et al. Impact of Glutathione and Vitamin B-6 in Cirrhosis Patients: A Randomized Controlled Trial and Follow-Up Study. Nutrients. 2020;12(7):1978. PMID: 32635181. DOI: 10.3390/nu12071978.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

Oral glutathione x liver detoxification, toxin elimination, and liver enzymes Evidence Grade C card
[Chamgap] Oral glutathione x liver detoxification, toxin elimination, and liver enzymes — Evidence Grade C·41. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/oral-glutathione-liver-detox/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.